Results 71 to 80 of about 12,211 (152)

Impact of treatment mechanism on octave MSDA pathway scores in patients receiving ocrelizumab or natalizumab

Multiple Sclerosis Journal - Experimental, Translational and Clinical
Objectives To compare MSDA Score and pathway scores between patients treated with ocrelizumab and natalizumab in real-world MS population. Methods We conducted a cross-sectional observational study of patients treated with ocrelizumab or natalizumab at a
Hora Heidari, Zhila Maghbooli, Aram Zabeti   +2 more
doaj   +1 more source

Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US

ClinicoEconomics and Outcomes Research, 2013
Machaon M Bonafede,1 Barbara H Johnson,1 Crystal Watson2 1Truven Health Analytics, Cambridge, MA, USA; 2Biogen Idec, Weston, MA, USA Objectives: To evaluate multiple sclerosis (MS)-related health care-resource utilization and costs prior to and after ...
Bonafede MM, Johnson BH, Watson C
doaj  

Retinal atrophy in multiple sclerosis is similar with extended versus standard interval natalizumab therapy. [PDF]

Mult Scler J Exp Transl Clin
McCormack B, Ezzedin O, Lin TY, Bacchetti A, Moretti GS, Lievers E, Gulati A, Davis S, Otero-Duran G, Bonair DJ, Pellegrini N, Gakis G, Filippatou A, Lambert CM, O'Donnell MM, Fitzgerald K, Sotirchos ES, Calabresi PA, Newsome SD, Mowry EM, Saidha S.   +20 more
europepmc   +1 more source

Early switching to ofatumumab avoids a rebound effect after natalizumab cessation in multiple sclerosis patients. [PDF]

Mult Scler J Exp Transl Clin
De Seze J, Bernard E, Betsch C, Nivoix Y, Bigaut K, Kremer L, Collongues N, Lanotte L, Ouallet JC.   +8 more
europepmc   +1 more source

Subcutaneous natalizumab administration in relapsing-remitting multiple sclerosis: results of EASIER 2 study. [PDF]

J Neurol
Filippi M, Grimaldi LME, Brescia Morra V, Conte A, Cordioli C, Totaro R, Lus G, Rini A, Marinelli F, Valentino P, Perini P, Marfia GA, Valente M, Malucchi S, Zanetta C, Pradelli L, Perini D, Santoni L, EASIER 2 study working Group.   +18 more
europepmc   +1 more source

Brain Immune Cell Composition in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy After Natalizumab: An Immunohistochemical Cohort Study. [PDF]

Neurol Neuroimmunol Neuroinflamm
Raabe BS, Stork L, Kutllovci A, Goelz SE, Metz I.   +4 more
europepmc   +1 more source

FDA's Approval Summary of the First Biosimilar to Natalizumab for the Treatment of Multiple Sclerosis and Crohn's Disease. [PDF]

J Clin Pharmacol
Delvadia PR, Nookala AR, Gottipati G, Sabarinath S, Uppoor RS, Mehta MU, Du X, Wang YC, Dokmanovic M, Myers R, Stevens J, Baldassari L, Lee P, Jawidzik L, Apparaju S, Seo S, Brahme NN, Schrieber SJ.   +17 more
europepmc   +1 more source

Absolute and Relative Quantification of Glycation on Biotherapeutic IgGs Using Heavy Isotope-Labeled Proteins. [PDF]

J Biomol Tech
Priya S, Popov M, Orlando R.
europepmc   +1 more source

Tysabri Observational Program (TOP): long-term safety and effectiveness of natalizumab treatment in relapsing-remitting multiple sclerosis over 15 years. [PDF]

J Neurol Neurosurg Psychiatry
Butzkueven H, Kappos L, Wiendl H, Trojano M, Spelman T, Greco A, Sun Z, Lasky T, TOP Investigators.   +8 more
europepmc   +1 more source

Does a monoclonal antibody targeting immune cells affect glutamatergic level in schizophrenia? A multimodal PET/MRS brain imaging study. [PDF]

Neuropsychopharmacology
Hindley G, Mizuno Y, Beck K, Carreira Figueiredo I, Pillinger T, Jeljeli S, Dunn J, Hammers A, Awais R, Sander K, Årstad E, Lythgoe DJ, Schubert JJ, Veronese M, Turkheimer F, Howes OD, Reis Marques T.   +16 more
europepmc   +1 more source